natgillin/translations-raw huggingface dataset:
centrifuging the maintained solution from step (o) and obtaining a collagen-containing precipitate therefrom; resuspending the collagen-containing precipitate from step (p) to a concentration of 1 to 30 mg/mL by resuspending said collagen-containing precipitate in a weakly acidic solvent or phosphate-buffered saline (PBS) and then maintaining the resuspended collagen-containing concentrate at 4° C.; 
HR P20131129 TI odležavanja tako titrirane otopine kod temperature od 30 do 37""C tijekom 4 sata do 1 dana, te potom centrifugiranja; te resuspendiranja tako istaloženog kolagena na koncentraciju od 1 do 30 mg/ mL u slabo kiselom otapalu ili PBS, te potom pohranjivanja na 4*C.
scrolling the solids through a conically converging section of the bowl after the cylindrical section and prior to the conically diverging screen section. 
pomicanje krutina kroz konusni konvergirajući dio omotača nakon cilindričnog dijela te prije konusnog divergirajućeg rešetkastog dijela.
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound chlorothalonil. 
spoja formule (I) [image] naznačen time da R1 je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i spoj mandipropamid.
stirring said washing and separating container (1) to facilitate the emulsion of the fluid components with an emulsion-forming system (104); 
Metoda u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje je element (104) za miješanje pasivno sredstvo koje vrši svoje djelovanje nakon miješanja spremnika (1) i djeluje po inerciji.
Use of (a) a long-acting B2-agonist as defined in any one of claims 1 and 3 to 6 and (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2, for the preparation of a medicament for simultaneous, concurrent, separate or sequential use in the treatment of a respiratory disease which is asthma, acute or chronic bronchitis, emphysema or chronic obstructive pulmonary disease (COPD) in a patient 
Uporaba (a) B2 agonist kako je definiran u bilo kojem od patentnih zahtjeva 1 i 3 do 7 1 (b) antagonista M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2, naznačena time, da je to uporaba za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju bolesti dišnih putova a koje su astma, akutni ili kronični bronhitis, emfizem, kronične opstruktivne plućne bolesti (COPD), bronhijalne hiperaktivnosti ili rinitisa kod bolesnika.
A method for inhibiting a CD40 ligand-mediated CD40 signaling pathway in a human CD40-expressing cell, said method comprising contacting said cell with an effective amount of a human anti-CD40 monoclonal antibody selected from the group consisting of: 
In vitro metoda inhibicije CD40 ligandom-posredovanog CD40 signalnog puta kod humane CD40-ekspresijske stanice, navedena metoda sadrži dovođenje u kontakt navedene stanice s učinkovitom količinom anti-CD40 monoklonalnog antitijela prema bilo kojem zahtjevu od 1 do 10.
granulating the materials from the step (3) using a dry granulation process, wherein the dry granulation process comprises: 
granuliranja materijala iz koraka (2) primjenom procesa suhe granulacije koji obuhvaća:
continuous infusion or bolus) or by subcutaneous injection (e.g. 
kontinuirana infuzija ili u bolusu) ili supkutanom injekcijom (na pr.
an inverse scanning unit (220) configured to inversely scan the 1D quantized coefficients in the unit of sub-block to generate a quantized transform block; 
inverznu jedinica za skeniranje (220) konfiguriranu za inverzno skeniranje jednodimenzionalnih kvantiziranih koeficijenata u jedinicama pod-blokova za generiranje kvantiziranog transformacijskog bloka;
A medication kit as claimed in claim 7, in which the at least one medicament carrier (2) is a blister pack (4). 
Medicinska garnitura prema zahtjevu 7, naznačena time, da je barem jedan nosač lijeka (2) u obliku blister pakiranja (4).
At the same time, the perforation means 32 have already open the lower surface of the capsule 24 and a produced beverage can be collected and drained through the draining channel 27. 
U isto vrijeme sredstva za pcrforiranje 32 su već otvorila donju plohu čahure 24 i proizvedeni napitak možc biti skupljen i odveden kroz kanal za odvođenje 27.
Medical formulation according to any of the claims 1 to 3, comprising, as daily dose: to 50 mg bark extract of cinnamomum zeylanicum; 
Medicinska formulacija prema zahtjevu 1, naznačena time što kao dnevnu dozu sadrži: - 1 do 50 mg ekstrakta kore cimeta;
The extended release dosage form of any one of claims 1 to 22, wherein the opioid analgesic is hydromorphone hydrochloride and the dosage form comprises from about 1 mg to about 100 mg of hydromorphone hydrochloride. 
Postupak prema zahtjevu 37, naznačen time da je opioidni analgetik hidromorfon hidroklorid i da oblik davanja sadrži od oko 1 mg do oko 100 mg hidromorfon hidroklorida.
the driving means comprise at least one crankshaft (352, 402) extended along the direction of a horizontal axis (Y1, Y2) where are mounted the connecting ends (364, 366, 374, 376 and 414, 416, 424, 426) of at least two pairs of opposed rods (360, 362, 370, 372 and 410, 412, 420, 422); 
- pogon sadrži najmanje jednu osovinu (352, 402) koja se pruža u smjeru vodoravne osi (Y1, Y2), gdje su ugrađeni povezujući krajevi (364, 366, 374, 376 i 414, 416, 424, 426) od u najmanju ruku dva para nasuprotnih štapova (360, 362, 370, 372 i 410, 412, 420, 422);
The compound of claim 1 selected from: and pharmaceutically acceptable salts and solvates thereof. 
Å u O i njegovih farmaceutski prihvatljivih soli i solvata. Spoj prema zahtjevu 1 izabran od: mI
In one example, the method may further comprise: calculating with the processor mechanism a displacement vector of the detected second user marking cell versus an ideal planar position of the detected second user marking cell; and detecting with the processor mechanism at least a third user marking cell on the form, wherein the third user marking cell is bounded by at least one indicium that is visible to the camera (see, e.g., user marking cells of form 400 in Figs. 4 and 6, user marking cells of form 700A of Fig. 7, user marking cells of form 800 of Fig. 8 and user marking cells of form 1000A of Fig. 10), and wherein the third user marking cell is detected based at least in part upon at least one of: (a) the displacement vector of the detected first user marking cell; and (b) the displacement vector of the detected second user marking cell. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što dodatno uključuje: izračunavanje procesorskim mehanizmom vektora pomaka detektirane druge ćelije za korisničku oznaku u odnosu na idealni planaran položaj detektirane druge ćelije za korisničku oznaku; i detektiranje procesorskim mehanizmom u najmanju ruku treće ćelije za korisničku oznaku na formularu (400, 700), gdje je treća ćelija za korisničku oznaku omeđena najmanje jednom bilješkom, vidljivom za kameru, te gdje se treću ćeliju za korisničku oznaku detektira na temelju u najmanju ruku dijelom najmanje jednog od: (a) vektora pomaka detektirane prve ćelije za korisničku oznaku; i (b) vektora pomaka detektirane druge ćelije za korisničku oznaku.
Use according to claim 14 wherein said excipient is selected from the group consisting of: ionizing agents; antioxidant agents; chelating agents; moisturizing agents; thermoviscosizing agents; decongestant agents; disinfectant and/or antimicrobial agents; flavouring and colorants. 
Upotreba u skladu s patentnim zahtjevom 14, naznačena time što navedenu pomoćnu tvar se bira iz skupine koju čine: ionizacijska sredstva; antioksidansi; kelirajuća sredstva; ovlaživači; termoviskozirajuća sredstva; dekongestivi; dezinficijensi i/ili antimikrobna sredstva; arome i boje.
The powder formulation according to claim 1 or 2, wherein the LABA is formoterol fumarate dihydrate, the ICS is beclometasone dipropionate and the anticholinergic is glycopyrronium bromide. 
Formulacija suhog praška prema patentnom zahtjevu 1 ili 2, naznačeno time da najmanje 90% mikroniziranih čestica aktivnih tvari ima volumni promjer jednak ili manji od 5,0 mikrona.
In 1975, Porath introduced immobilized metal ion affinity chromatography (IMAC) for fractionating proteins [J. Porath, J. Carlsson, I. Olsson, and G. Belfrage, Nature (London) 258, 598-599 (1975)]. 
Godine 1975., Porath je predstavio ovaj tip kromatografije kao metodu za frakcioniranje proteina [J. Porath, J. Carlsson, I. Olsson i Belfrege, Nature (London) 258. 598-599 (1975)].
A PDE7 inhibitor for use in treating a movement abnormality associated with the pathology of a neurological disorder in a patient in need thereof which PDE7 inhibitor is one of the following formulas: formula 6E; formula 6F; formula 6G; or formula 6H, or a pharmaceutically acceptable salt thereof. 
Inhibitor PDE7 namijenjen upotrebi u liječenju abnormalnosti kretanja povezanog s patologijom neurološkog poremećaja u bolesnika kojem je takvo liječenje potrebno, naznačen time, da inhibitor PDE7 ima jednu od sljedećih formula:
The method of Claim 1, wherein the 5' and/or the 3' end of at least the first CRISPR spacer of said CRISPR locus of said parent bacterial strain is compared with said modified CRISPR locus of said bacteriophage resistant variant strains. 
Postupak prema zahtjevu 1, naznačen time da se 5' i/ili 3' završetak barem prve CRISPR razmaknice navedenog CRISPR lokusa navedenog matičnog bakterijskog soja uspoređuje s navedenim modificiranim CRISPR lokusom navedenih varijanti sojeva rezistentnih na bakteriofag.
A ship as claimed in claim 5, characterized in that the purification unit (2', 2") comprises a coarse filter (12', 12") arranged upstream of the effluent circuit (3', 3") 
Brod prema zahtjevu 5, naznačen time da jedinica za pročišćavanje (2', 2") sadrži grubi filter (12', 12") smješten uzvodno od kruga efluenta (3', 3").
is a hydrogen atom, a hydroxy group, a C1 to C6 alkoxy group optionally having substituent(s), or a C1to C6 alkyl group optionally having substituent(s); 
R' je atom vodika, hidroksigrupa, C, do Cg alkoksi grupa koja po izboru ima supstituent(e), ili C, do C4 alkil grupa koja po izboru ima supstituent(e);
disintegrant, and 
sredstva za raspadanje, te
The mineral composition according to claim 1, wherein the mineral powder (c) is a graphite powder. 
Mineralni sastav prema zahtjevu 1, naznačen time da je mineralni prah (c) prah grafita, poželjno ekspandiranmi grafitni prah ili zbijeni ekspandirani grafitni prah.
In other embodiments, the skin disease or disorder is a chronic wound. 
Farmaceutski pripravak za uporabu prema zahtjevu 33, naznačen time da je kožna bolest ili poremećaj kronična rana.
which is further converted to chloromethyl oxazolidinone compound of formula VII and is crystallized 
(VIN) koji se nadalje pretvara u klorometil-oksazolidinon spoj formule VII:
q is an integer of 0 to 1, and n is an integer of 1 to 4, wherein the active agent is attached to a group containing a second functional group (FG2) that can react with the FG1, wherein the FG2 is selected from the group consisting of: acetylene, hydroxylamine, azide, aldehyde, hydrazine, ketone, and 
R, je vodik, Cig alkil, Cig alkil aril ili Cig alkil heteroaril, rip su svaki neovisno cijeli broj od 0 do 6, qje cijeli broj od O do 1,injecijeli broj od 1 do 4, pri čemu je aktivno sredstvo vezano na skupinu koja sadržava drugu funkcionalnu skupinu (FG2) koja može reagirati s FGI1, pri čemu je FG2 odabran iz skupine koju čine: acetilen, hidroksilamin, azid, aldehid, hidrazin, keton, i pri čemu je aktivno sredstvo vezano na skupinu koja sadržava FG2 preko ili [ZCH;CH20 (CH2CH;0),,CH2CH2Z]-, pri čemu,
Movement of the handle 25 in the direction of the arrow results in the operating fork 23 moving upwards as a result of expansion of the springs 59, 60, so that the ball 22 (see Fig. 
Pomicanje ručke 25 u smjeru strelice rezultira time da se radna vilica 23 pokreće prema gore kao rezultat ekspanzije (produljenja) opruga 59, 60, tako da se kugla 20 (vidi sl.
and R5 are independently selected from H and C1-4 alkyl, and additionally one of the R4 or R5 groups may represent aryl or C3-8 cycloalkyl-C0-6 alkyl, and additionally two R4 and R5 groups on a same C atom may be bound together forming with said C atom a C3-8 cycloalkyl group; 
R4 1 Rs su neovisno odabrani od H i C,.4 alkila te dodatno jedne od R, ili Rs skupina mogu predstavljati aril ili C3.8 cikloalkil-C9.4 alkila, i dodatno dvije R4 1 Rs skupina na istom C atomu mogu biti vezane zajedno tvoreći s rečenim C atomom C3.g cikloalkilnu skupinu;
According to another aspect of the present invention, the methanol content in said fluid may be at least 0.05% by weight, such as at least 0.1% by weight, and preferably at least 0.2% by weight, such as at least 0.3% by weight, and even more preferably at least 0.5% methanol by weight, such as at least 1% by weight. 
Metoda u skladu s patentnim zahtjevom 40, pri čemu je sadržaj metanola u navedenoj tekućini najmanje 0,05 % prema težini, kao što je najmanje 0,1 % prema težini, a poželjno najmanje 0,2 % prema težini, kao što je najmanje 0,3 % prema težini, a još poželjnije najmanje 0,5 % prema težini, kao što je najmanje 1 % prema težini.
a pharmaceutically acceptable excipient or carrier. A compound or a pharmaceutically acceptable salt according to any of claims 1 to 8 or pharmaceutical composition thereof, for use in treating an inflammatory or immune-related physiological disorder, symptom or disease in a patient in need of such treatment. 
Spoj ili farmaceutski prihvatljiva sol prema bilo kojem od patentnih zahtjeva 1 do 18 ili njegova farmaceutska kompozicija, naznačena time, što se koristi za primjenu u liječenju inflamatornog ili fiziološkog poremaćaja, simptoma ili bolesti povezanog sa imunološkim sustavom kod pacijenta kod kojeg postoji potreba za takvim tretmanom.
Furthermore, the underside (29) of the sealing attachment (25) is complementary to the upper side of the bottom of the recess (12) defining the break-away area (7). 
Poklopac limenke u skladu s patentnim zahtjevom 3 ili 4, naznačen time što se prstenasta stijenka (11) pruža na dolje preko unutarnje površine (16) prstenastog nabora (15).
A pharmaceutical composition according to any one of claims 1-13, wherein such single dose form comprises one or more antidiabetic compounds selected from the group consisting of incretin hormones or mimics thereof, beta-cell imidazoline receptor antagonists, and short-acting insulin secretagogues. 
Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-13, naznačena time što takav pojedinačni dozni oblik sadrži jedan ili više antidijabetičkih spojeva izabranih iz grupe koju čine inkretin hormoni ili spojevi koji ga imitiraju, antagonisti receptora za imidazolin beta stanica i insulinski sekretagogi sa kratkim djelovanjem.
The compound for use according to claim 14, wherein said second active agent is selected from the group consisting of a DNA-hypomethylating agent, a therapeutic antibody that specifically binds to a cancer antigen, a hematopoietic growth factor, a cytokine, an antibiotic, a cox-2 inhibitor, an immunomodulatory agent, an anti-thymocyte globulin, an immunosuppressive agent, and a corticosteroid or a pharmacological derivative thereof or wherein said second active agent is an anti-PDl antibody or an anti-PDLl antibody. 
Spoj za uporabu u skladu s patentnim zahtjevom 14, pri čemu je navedena druga aktivna tvar izabrana iz grupe koja sadrži DNK-hipometilativnu tvar, terapeutsko antitijelo koje se posebno veže za antigen raka, hematopoetski faktor rasta, citokin, antibiotik, cox-2 inhibitor, imunomodulator, antitimocitni globulin, imunosupresiv i kortikosteroid ili njegov farmakološki derivat ili pri čemu je navedena druga aktivna tvar anti-PDI antitijelo ili anti-PDLI antijelo.
Another process (Process B) for preparing a dihydrotetrabenazine of the invention comprises subjecting a compound of the formula (III); to conditions for ring-opening the 2,3-epoxide group in the compound of the formula (III), and thereafter where required separating and isolating a desired dihydrotetrabenazine isomer form. 
CH,O CH,O (ED uvjetima za otvaranje prstena 2,3 -epoksid skupine u spoju formule (III) i nakon toga, kada je to potrebno, odjeljuje se i izolira željeni izomerni oblik dihidrotetrabenazina.
continuously acquiring and recording, by a plurality of measurement stations equipped with vibroacoustic sensors discretely located along the pipeline, of vibroacoustic signals due to the vibrations generated by contact/friction of the pig device with the welding seams of the pipeline and/or with other physical variations locally present in multiple pipe sections of the pipeline; 
– kontinuiranog dobivanja i snimanja, uz pomoć više mjernih postaja (14), opremljenih vibroakustičnim senzorima, postavljenim pojedinačno po cjevovodu (12), vibroakustičnih signala nastalih zbog tranzijenata hidrauličnog tlaka, i/ili zbog vibracija koje generira prasica koja se kreće (10) u koracima kontakta odnosno trenja na varnim šavovima, i/ili zbog drugih fizičkih varijacija prisutnih lokalno u više cijevnih odjeljaka cjevovoda (12);
vi) repeating steps ii) to v) with subsequent gloves to build up a stack of interfolded gloves within said recess. 
HR P20180218 T1 vi) ponavljanje koraka ii) do v) sa slijedećim rukavicama da se napravi snop međusobno presavijenih rukavica unutar navedenog udubljenja.
R8, R9, R10 and R11 independently from each other stand for H, or C1-C6 alkyl; or any two of R8, R9, R10 and R11 together with the carbon atom to which they are bound may form a 3-6 membered saturated carbocyclic ring; 
R8, R9, R10 1 R11 međusobno neovisno predstavljaju H, ili C,-Cg alkil; ili bilo koja dva od R8, R9, R10 i R11 zajedno s atomom ugljika na kojega su vezani, mogu tvoriti 3-člani do 6-člani zasićeni karbociklički prsten;
The method of any preceding claim, wherein the neural multipotent, unipotent or somatic cell so obtained possesses one or more of the following characteristics: 
Postupak prema zahtjevima 1, 2 ili 4 do 6, pri čemu tako dobivena NSLC sadrži jednu ili više od sljedećihrakteristika:
The value of the substrate is considerably lower than the veneer itself. 
Vrijednost podloge je znatno manja od vrijednosti samog furnira.
The compound of any one of claims 1-25, wherein R3 is at the 3-position and is selected from the group consisting of 3-dimethylaminopropoxy, 2-dimethylaminoethoxy, 2-hydroxyethoxy,2,3-dihydroxypropoxy, 2-dimethylaminoethylamino and 3-dimethylaminopropylamino. 
Spoj prema bilo kojem zahtjevu 1 do 23, naznačen time, da R3 je na poziciji 3 i odabran je iz skupine koja sadrži 3-dimetilaminopropoksi, 2-dimetilaminoetoksi, 2-hidroksietoksi, 2,3-dihidroksipropoksi, 2-dimetilaminoetilamino i 3-dimetilaminopropilamino.
The method of claim 1 wherein said cancer is selected from bladder cancer, breast cancer, colorectal cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, pancreas/gall bladder cancer, prostate cancer, thyroid cancer, osteosarcoma, rhabdomyosarcoma, MFH/fibrosarcoma, glioblastomas/astrocytomas, melanoma, and mesothelioma. 
Spoj prema zahtjevu 9, za uporabu u terapiji za liječenje raka mjehura, raka dojke, kolorektalnog raka, raka želuca, raka glave 1 vrata, raka bubrega, raka jetre, raka pluća, raka jajnika, raka gušterače/žučnog mjehura, raka prostate, raka štitnjače, osteosarkoma, rabdomiosarkoma, MFH/fibrosarkoma, glioblastoma/astrocitoma, melanoma ili mezotelioma.
The image lines 12, 13, 14 comprise a plurality of image lines 15 provided under the lenses 8, 9, 10 . 
Identifikacijski dokument (1) prema zahtjevu 7, gdje su leće (8, 9, 10) niza (7) leće oblikovane sferno.
20 for the downlink assignment case, assuming that a CIF field is added to the formats. In another alternative implementation according to another embodiment of the invention, two predefined CIF codepoints are used for indication that the DCI format (resource assignment) comprises information identifying at least one DL component carrier which is to be activated respectively deactivated. If the codepoint of the CIF field is “111”, the DCI format (resource assignment) indicates the activation of the at least one downlink component carrier identified by the identifier field, whereas when if the codepoint of the CIF field is “110” the DCI format indicates the deactivation of the at least one downlink component carrier identified by the identifier field in the DCI format. 
Komunikacijski uređaj sukladno zahtjevu 9, naznačen time da informacija o raspoređivanju resursa sadrži CRC polje koje je maskirano s privremenim identifikatorom radijske mreže, RNTI, koji je dodijeljen komunikacijskom uređaju za aktivaciju i deaktivaciju nosača komponenti silazne veze. HR P20181635 T1 Komunikacijski uređaj sukladno zahtjevu 15, naznačen time da barem jedna kodna točka polja indikatora nosača, CIF, informacije o raspoređivanju resursa ukazuje da li informacija o raspoređivanju resursa uključuje bit-masku za aktivaciju ili deaktivaciju nosača komponenti silazne veze ili ne koristi li se dodjeljivanje resursa uzlazne veze za aktivaciju ili deaktivaciju nosača komponenti silazne veze i dodjeljuje samo resurse uzlazne veze.
The compound according to claim 2 or a pharmacologically acceptable salt thereof, wherein A is a cyclohexyl group which may be substituted by one to three identical or different groups selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, a C1 to C6 alkoxy group, an aryloxy group, and a heterocyclyloxy group. 
Spoj u skladu sa patentnim zahtjevom 2 ili njegova farmakološki prihvatljiva sol, gdje A je cikloheksil grupa koja može biti supstituirana jednom do tri identične ili različite grupe odabrane od fluoro grupe, hidroksilne grupe, C1 do C6 alkil grupe, C1 do C6 alkoksi grupe, ariloksi grupe, i heterocikliloksi grupe.
A compound, or a pharmaceutically acceptable salt of the compound, wherein the compound has the structure of Formula I: and wherein: 
Spoj, ili farmaceutski prihvatljiva sol spoja, naznačen time što spoj ima strukturu Formule I:
A compound for use according to claim 1, wherein the compound is 
Spoj za upotrebu prema Zahtjevu 1, pri čemu taj spoj predstavlja t>&
7 . According to another major feature of the present invention, the container 151 has a bottom 156 that is open and provided with a step-like configuration which, in conjunction with a step-like configuration at the upper mouth of the cavity 152, is intended to hold and retain the capsule 200, as this is best shown in FIGS. 
Prema sljedećoj glavnoj karakteristici ovog izuma spremnik 151 ima dno 156, koje je otvoreno i ima stepeničastu konfiguraciju koja, u sprezi sa stepeničastom konfiguracijom na gornjem otvoru šupljine 152, treba držati i podržavati kapsulu 200, što je na najbolji način prikazano na Slikama 5 1 6.
keeping said viable biological material at the hydrostatic pressure for a time period between 10 seconds to 150 minutes; 
(b) držanje navedenog biološkog materijala na hidrostatskom tlaku kroz vremensko razdoblje između 10 sekundi 1 150 minuta;
Examples of metal salts include lithium, sodium, potassium, magnesium salts and the like. 
Primjeri metanih soli su soli litija, natrija, kalija, magnezija i slične.
A composition according to claim 5, wherein the ratio (w/w) of compound to disaccharide is from about 1:100 to about 1:400. 
Smjesa prema zahtjevu 5, naznačena time, što odnos (tež,/tež.) spoja prema disaharidu iznosi od 1:100 do 1:400.
A compound according to claim 1 or 2 selected from: 6-Amino-9-benzyl-2-(methylsulfonimidoyl)-7H-purin-8-one; 
Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da je odabran iz skupine koju čine:
1, the electrode control device 44 can be connected to the conditioning element 32 to receive therefrom the stabilized voltage value UA′ relating to the arc voltage UA and as a function of the latter to control the positioning device 46 . 
Postupak prema patentnom zahtjevu 12, naznačen time što se aktiviranjem uređaja za pozicioniranje (46) upravlja preko uređaja za upravljanje elektrodom (44) kao funkcije napona luka (UA) i primljenog referentnog napona (UR).